A Bayesian network meta-analysis of statins, ezetimibe, and PCSK9 inhibitors revealed that PCSK9 inhibitors had the best surface under the cumulative ranking curve (SUCRA) to prevent MACE (a combination of stroke, MI, and all-cause mortality; primary endpoint), followed by statins (SUCRA 75%) and ezetimibe plus statins (SUCRA 51%) [6]. This evidence concerns the gene PCSK9 and stroke disorder.